Abstract
Nanoparticle Formulations of siRNA: The Next Generation of Targeted Therapy for Lymphomas and Leukemias?
Highlights
Despite the success of targeted therapies, many genomic alterations are considered “undruggable”
Nanoparticles can protect the small interfering RNA (siRNA) from degradation and can facilitate endosomal escape once the siRNA has been endocytosed by the target cells (Kanasty et al, 2013)
No siRNA-based therapies have been approved for clinical use
Summary
Despite the success of targeted therapies, many genomic alterations are considered “undruggable”. The effects of siRNA are temporary (days to weeks) and not permanent; such temporary effects may not last long enough to alter the disease course.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
